To preempt the common relapses caused by resistant tumor variants [14], the BRAFV600 inhibitors were then combined with MEK inhibitors (MEKi), i.e., cobimetinib (cobi), trametinib (tram) [7], or binimetinib, which has been shown to increase progression-free survival significantly [13,15,16]. This evidence concerns the gene MAP2K7 and neoplasm.